15 Jan 2021 Imfinzi approved in the EU for less-frequent, fixed-dose use in unresectable non-small cell lung cancer
14 Jan 2021 Genmab Achieves USD 40 Million Milestone in Collaboration with AbbVie
14 Jan 2021 Alexion Provides Update on Phase 3 Study of ULTOMIRIS® (ravulizumab-cwvz) in Hospitalized Patients with Severe COVID-19
13 Jan 2021 Jounce Therapeutics Announces Initiation of Phase 1 INNATE Study of JTX-8064 (LILRB2/ILT4 Inhibitor) Monotherapy and PD-1 Inhibitor Combination Therapy in Patients with Advanced Solid Tumors
13 Jan 2021 LEO Pharma initiates head-to-head study to evaluate brodalumab vs. guselkumab in adult patients with moderate-to-severe psoriasis who have inadequate response to ustekinumab
13 Jan 2021 Celltrion Group announces positive top-line efficacy and safety data from global Phase II/III clinical trial of COVID-19 treatment candidate CT-P59
13 Jan 2021 UroGen Pharma and MD Anderson Announce Strategic Research Collaboration to Advance Investigational Treatment for High-Grade Bladder Cancer
12 Jan 2021 Biond Biologics and Sanofi Enter into Global Licensing Agreement for BND-22, a Novel Immune Checkpoint Inhibitor Targeting the ILT2 Receptor
12 Jan 2021 DiosCURE to Develop Highly Specific Single-Chain Antibodies Against SARS-CoV-2, Lead Candidates Described in Science Publication
12 Jan 2021 Vir Biotechnology and GSK Announce NHS-Supported AGILE Study to Evaluate VIR-7832 in the Early Treatment of COVID-19
12 Jan 2021 AvantGen Announces Licensing of Its Anti-SARS-CoV-2 Antibodies to IGM Biosciences for COVID-19 Therapy Development
12 Jan 2021 Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene
11 Jan 2021 Lilly's Donanemab Slows Clinical Decline of Alzheimer's Disease in Positive Phase 2 Trial
11 Jan 2021 ATP and Biolojic Design Launch Aulos Bioscience to Develop Highly Differentiated IL-2 Antibody Approach to Fighting Cancer
11 Jan 2021 Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L
07 Jan 2021 Risankizumab (SKYRIZI®) Demonstrates Significant Improvements in Clinical Remission and Endoscopic Response in Two Phase 3 Induction Studies in Patients with Crohn's Disease
07 Jan 2021 REMD Biotherapeutics Completes Enrollment and Announces Top-line Results of a Phase 2 Clinical Study of Volagidemab (REMD-477) in Patients with Type 1 Diabetes
06 Jan 2021 Novel Treatment Pioneered by MSK Kids Researchers Receives FDA Approval for Patients with High-Risk Neuroblastoma
06 Jan 2021 Mersana Therapeutics Announces Corporate and Pipeline Updates and 2021 Goals and Anticipated Milestones
06 Jan 2021 Chemomab Announces Positive Phase Ib Results of its SPARK study testing CM-101 in NAFLD patients
06 Jan 2021 Y-Biologics signed License Agreement with 3D Medicines for T cell bispecific engager in Greater China territory
05 Jan 2021 Risankizumab (SKYRIZI®) Phase 3 Results Demonstrate Improvements in Disease Activity Across Joint and Skin Symptoms Among Psoriatic Arthritis Patients
05 Jan 2021 Harpoon Therapeutics Doses First Patient with HPN328, an Anti-DLL3 T Cell Engager for Treatment of Small Cell Lung Cancer and other DLL3-Associated Tumors
05 Jan 2021 F-star Therapeutics Announces First Patient Dosed in FS222 Phase 1 Clinical Trial
05 Jan 2021 Genmab Announces Phase 3 Trial of Tisotumab Vedotin in Recurrent or Metastatic Cervical Cancer

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2019 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up